Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain

被引:156
作者
Butler, JS [1 ]
Loh, SN [1 ]
机构
[1] SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA
关键词
D O I
10.1021/bi026635n
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 DNA binding domain (DBD) contains a single bound zinc ion that is essential for activity. Zinc remains bound to wild-type DBD at temperatures below 30 degreesC; however, it rapidly dissociates at physiological temperature. The resulting zinc-free protein (apoDBD) is folded and stable. NMR spectra reveal that the DNA binding surface is altered in the absence of Zn2+. Fluorescence anisotropy studies show that Zn2+ removal abolishes site-specific DNA binding activity, although full nonspecific DNA binding affinity is retained. Surprisingly, the majority of tumorigenic mutations that destabilize DBD do not appreciably destabilize apoDBD. The R175H mutation instead substantially accelerates the rate of Zn2+ loss. A considerable fraction of cellular p53 may therefore exist in the folded zinc-free form, especially when tumorigenic mutations are present. ApoDBD appears to promote aggregation of zinc-bound DBD via a nucleation-growth process. These data provide an explanation for the dominant negative phenotype exhibited by many mutations. Through a combination of induced p53 aggregation and diminished site-specific DNA binding activity, Zn2+ loss may represent a significant inactivation pathway for p53 in the cell.
引用
收藏
页码:2396 / 2403
页数:8
相关论文
共 42 条
[1]   p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines [J].
Aurelio, ON ;
Kong, XT ;
Gupta, S ;
Stanbridge, EJ .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (03) :770-778
[2]   Metallothionein: Early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma [J].
Bruewer, M ;
Schmid, KW ;
Krieglstein, CF ;
Senninger, N ;
Schuermann, G .
WORLD JOURNAL OF SURGERY, 2002, 26 (06) :726-731
[3]  
Buckley J. S., 1995, SPE ADV TECH SER, V3, P53, DOI [10.2118/26675-PA, DOI 10.2118/26675-PA]
[4]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256
[5]   Thermodynamic stability of wild-type and mutant p53 core domain [J].
Bullock, AN ;
Henckel, J ;
DeDecker, BS ;
Johnson, CM ;
Nikolova, PV ;
Proctor, MR ;
Lane, DP ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14338-14342
[6]   Requirement for p53 and p21 to sustain G2 arrest after DNA damage [J].
Bunz, F ;
Dutriaux, A ;
Lengauer, C ;
Waldman, T ;
Zhou, S ;
Brown, JP ;
Sedivy, JM ;
Kinzler, KW ;
Vogelstein, B .
SCIENCE, 1998, 282 (5393) :1497-1501
[7]   Carbon dioxide enhanced ultrasonography of hepatic haemangiomas [J].
Chen, WT ;
Chen, RC ;
Wang, CK ;
Tu, HY ;
Chiang, LC ;
Chen, PH .
CLINICAL RADIOLOGY, 1998, 53 (04) :281-286
[8]   In vitro structure-function analysis of the beta-strand 326-333 of human p53 [J].
Chene, P ;
Mittl, P ;
Grutter, M .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 273 (04) :873-881
[9]   CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS [J].
CHO, YJ ;
GORINA, S ;
JEFFREY, PD ;
PAVLETICH, NP .
SCIENCE, 1994, 265 (5170) :346-355
[10]  
DeMoor JM, 2000, CELL MOL BIOL, V46, P367